Skip to content

Live Events

Live Events

Live Events

Live Events

MEC Plus Full List View

By pinki@katapult.biz / February 16, 2025

MEC Plus

Events

Speciality

Type of Media

Author / Speaker

Title

Search Entries:

«
1
…
6
7
8
9
10
…
100
»

Global Oncology: Impact and Updates

Global Oncology: Impact and Updates

Manoj Menon, MD

Clinical Applications for Liquid Biopsy in
GU Cancers Update

Clinical Applications for Liquid Biopsy in GU Cancers Update

Rafee W. Talukder, MD

Bladder/Urothelial Cancer Updates

Bladder/Urothelial Cancer Updates

Petros Grivas, MD

Prostate Cancer Updates

Prostate Cancer Updates

Hiba Khan, MD

Renal Cell Carcinoma Updates

Renal Cell Carcinoma Updates

Scott Tykodi, MD

ASCO GI 2024 Updates

ASCO GI 2024 Updates

David B. Zhen, MD

Head and Neck Cancer 2024 Updates

Head and Neck Cancer 2024 Updates

Cristina P. Rodriguez, MD

BRAF and NTRK Inhibitors in NSCLC

BRAF and NTRK Inhibitors in NSCLC

Liza C. Villaruz, MD

Exon 20 Insertions - What Will be the Ideal Therapy?

Exon 20 Insertions - What Will be the Ideal Therapy?

Zofia Piotrowska, MD

STK11, KEAP and TP53 as Co-Mutations with Bad Prognosis - Is there a Predictive Role?

STK11, KEAP and TP53 as Co-Mutations with Bad Prognosis - Is there a Predictive Role?

Ferdinandos Skoulidis, MD, PhD

Resistance to KRAS Inhibitors

Resistance to KRAS Inhibitors

Matthew Gubens, MD

The Era of Antibody-Drug Conjugates (ADCs) and Bi-Specifics

The Era of Antibody-Drug Conjugates (ADCs) and Bi-Specifics

Jyoti Patel, MD

Role of Radiation Therapy in SCLC

Role of Radiation Therapy in SCLC

Puneeth Iyengar, MD

The Future of SCLC Treatment: Potential Agents and Where Are We Going?

The Future of SCLC Treatment: Potential Agents and Where Are We Going?

Misty Shields, MD, PhD

Treatment for SCLC in 2024: Where Are We At?

Treatment for SCLC in 2024: Where Are We At?

Christine L. Hann, MD

Progress in Biomarkers for SCLC – Are We Ready for Implementation into Routine Clinical Practice?

Progress in Biomarkers for SCLC – Are We Ready for Implementation into Routine Clinical Practice?

Ticiana Leal, MD

Moving the Bar Beyond PACIFIC. What is the Best Consolidation Therapy for People with Actionable and Non-Actionable Genes?

Moving the Bar Beyond PACIFIC. What is the Best Consolidation Therapy for People with Actionable and Non-Actionable Genes?

Tom Stinchcombe, MD

Combining Immunotherapy with Radiation for LA-NSCLC

Combining Immunotherapy with Radiation for LA-NSCLC

Megan Daly, MD

Assessing Resectability in Stage III NSCLC

Assessing Resectability in Stage III NSCLC

Linda Martin, MD

Update Progress in Targeted Therapies for Early-Stage NSCLC

Update Progress in Targeted Therapies for Early-Stage NSCLC

Lyudmila Bazhenova, MD

Which Patients Need Adjuvant Therapy?

Which Patients Need Adjuvant Therapy?

Karen Reckamp, MD

Debate- Is Perioperative Immunotherapy the New Standard of Care? No.

Debate- Is Perioperative Immunotherapy the New Standard of Care? No.

Hossein Borghaei, DO

Debate- Is Perioperative Immunotherapy the New Standard of Care? Yes.

Debate- Is Perioperative Immunotherapy the New Standard of Care? Yes.

Rachel E. Sanborn, MD

Perioperative Chemo/Immunotherapy and Surgical Outcomes

Perioperative Chemo/Immunotherapy and Surgical Outcomes

Jay M. Lee, MD

What is the Best Way to Assess Response to Therapy? Is Complete Pathologic Response the Best Surrogate?

What is the Best Way to Assess Response to Therapy? Is Complete Pathologic Response the Best Surrogate?

Lynette M. Sholl, MD

Assessing the Cancer Risk of Lung Nodules by Proteomic or Gene Expression Platforms

Assessing the Cancer Risk of Lung Nodules by Proteomic or Gene Expression Platforms

Matthew Smeltzer, PhD

Incidental Pulmonary Nodule Programs (IPNs) – What are Best Practices for Monitoring and Diagnosing?

Incidental Pulmonary Nodule Programs (IPNs) – What are Best Practices for Monitoring and Diagnosing?

Gerard Silvestri, MD

Existing and Emerging Tests for Cancer Interception: How Low do We have to Go (with the LOD)? Does Methylation Help?

Existing and Emerging Tests for Cancer Interception: How Low do We have to Go (with the LOD)? Does Methylation Help?

Triparna Sen, PhD

Lung Cancer Screening Programs: How do We ‘Take it to the Next Level’ to Improve Lung Cancer Outcomes?

Lung Cancer Screening Programs: How do We ‘Take it to the Next Level’ to Improve Lung Cancer Outcomes?

Claudia I. Henschke, MD, PhD

B-Cell NHL (Aggressive)-Relapsed (CAR T versus Bispecifics?)

B-Cell NHL (Aggressive)-Relapsed (CAR T versus Bispecifics?)

Julio C. Chavez, MD, MS

Displaying 211 - 240 of 2,995

«
1
…
6
7
8
9
10
…
100
»

← Previous View

6619 South Dixie Highway #341
Miami, FL 33143

Phone: 305.663.1628
Email: info@meccinc.com

Userful Links

Live Events

Categories

About Us

Why Subscribe
About Us
Accreditation

© 2025 MEC Inc. All rights reserved | Digital Marketing by Katapult Marketing

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok